Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT-OL long-term open-label bosentan extension in inoperable CTEPH
2005-002900-40Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bosentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Long-term efficacy and Long-term tolerability and safety. Started Nov 2005; status: completed.
02
Drugs
bosentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2005-002900-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002900-40.